Skip to content

Transversalis Fascia Plane Block Versus Intrathecal Morphine for Postoperative Analgesia in Total Abdominal Hysterectomy

Ultrasound-Guided Transversalis Fascia Plane Block Versus Intrathecal Morphine for Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy: A Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07201272
Enrollment
60
Registered
2025-10-01
Start date
2025-10-01
Completion date
2026-04-01
Last updated
2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transversalis Fascia Plane Block, Intrathecal Morphine, Postoperative Analgesia, Total Abdominal Hysterectomy

Brief summary

This study aims to compare the ultrasound-guided transversalis fascia plane (TFP) block and intrathecal morphine for postoperative analgesia in patients undergoing total abdominal hysterectomy (TAH).

Detailed description

Total abdominal hysterectomy (TAH) is a commonly performed major surgical procedure that results in substantial postoperative pain and discomfort. Postoperative pain, if not treated promptly, can impair the patient's ability to ambulate which may lead to adverse effects such as thromboembolism, myocardial ischemia, and arrhythmia. Intrathecal opioids are synergistic with local anesthetics and intensify the sensory block without increasing the sympathetic block. Morphine, which is relatively less hydrophobic than other opioids, has a longer residence time in the cerebrospinal fluid and therefore may reach rostral sites over a longer period than other opioids. Ultrasound-guided interfascial plane blocks are often used in multimodal analgesia regimens. Local anaesthetic injection into the transversalis fascia plane (TFP) anesthetizes the proximal branches of T12 and L1 which targeted in the plane between the transversus abdominis muscle and the transversalis fascia.

Interventions

Patients will receive spinal anesthesia (using 3.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.

DRUGMorphine

Patients will receive spinal anesthesia (using 3 mL of hyperbaric bupivacaine 0.5%) + (75 µg morphine diluted in 0.5ml saline) with sham block at the end of surgery.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 65 years. * American Society of Anesthesiology (ASA) physical status I-II. * Women undergoing total abdominal hysterectomy (TAH) under spinal anesthesia.

Exclusion criteria

* History of allergies to local anesthetics. * Local infection at the site of injection. * Bleeding disorders. * History of chronic use of analgesic. * Physical or mental conditions. * Hepatic, renal or cardiac disease. * Contraindication to spinal anesthesia.

Design outcomes

Primary

MeasureTime frameDescription
Time to the 1st rescue analgesia24 hours postoperativelyTime to the first request for the rescue analgesia (time from the end of surgery to first dose of morphine administrated).

Secondary

MeasureTime frameDescription
Total morphine consumption24 hours postoperativelyRescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS)\> 3 to be repeated after 30 min if pain persists until the NRS \< 4.
Degree of pain24 hours postoperativelyEach patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS). NRS (0 represents no pain while 10 represents the worst pain imaginable). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 8, 12, 18, and 24 h postoperatively.
Incidence of adverse events24 hours postoperativelyIncidence of adverse events such as bradycardia, hypotension, pruritis, nausea, vomiting, respiratory depression, or any other complication will be recorded.

Countries

Egypt

Contacts

Primary ContactMohammed S Elsharkawy, MD
mselsharkawy@med.tanta.edu.eg00201148207870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026